Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;11(7):e007309.
doi: 10.1136/jitc-2023-007309.

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

Harriet M Kluger  1 , Hussein Tawbi  2 , David Feltquate  3 , Theresa LaVallee  4 , Naiyer A Rizvi  5 , Elad Sharon  6 , Jeffrey Sosman  7   8 , Ryan J Sullivan  9   10
Affiliations

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

Harriet M Kluger et al. J Immunother Cancer. 2023 Jul.

Erratum in

Abstract

The need for solid clinical definitions of resistance to programmed death 1 or its ligand (PD-(L)1) inhibitors for clinical trial design was identified as a priority by the Society for Immunotherapy of Cancer (SITC). Broad consensus efforts have provided definitions for primary and secondary resistance and resistance after stopping therapy for both single-agent PD-(L)1 inhibitors and associated combinations. Validation of SITC's definitions is critical and requires field-wide data sharing and collaboration. Here, in this commentary, we detail current utility and incorporation of SITC's definitions and discuss the next steps both the society and the field must take to further advance immuno-oncology drug development.

Keywords: Clinical Trials as Topic; Drug Therapy, Combination; Guidelines as Topic; Immunotherapy; Tumor Escape.

PubMed Disclaimer

Conflict of interest statement

Competing interests: HMK—Consulting fees: Iovance, Immunocore, Celldex, Array Biopharma, Merck, Elevate Bio, Instil Bio, Bristol Myers Squibb, Clinigen, Shionogi, Chemocentryx, Calithera, Signatero. HT—Consulting fees: Genentech/Roche, Bristol Myers Squibb, Novartis, Merck, Pfizer, Eisai, Karyopharm, Boxer Capital; Contracted research: Genentech/Roche, Bristol Myers Squibb, Novartis, Merck, GSK. DF—Salary and employment: Palleon Pharmaceuticals; Ownership interest less than 5%: Palleon Pharmaceuticals.TL—Salary and employment: Coherus Biosciences; IP rights: AstraZeneca, Parker Institute for Cancer Immunotherapy, Celldex, EntreMed; Consulting fees: TRex Bio, Grey Wolf Therapeutics, Exosis, LisCure Biosciences, BiOne Cure, Inovio, 1440 Foundation; Ownership interest less than 5%: AstraZeneca, Coherus Biosciences. JS—Consulting fees: Array, Nektar, Jazz, Iovance, Apexigen, Eisai; Contracted research: Bristol Myers Squibb, Amphivena, PACT. NAR—Salary and employment: Synthekine; Royalty: Personal genome Diagnostics; IP Rights: Determinants of cancer response to immunotherapy (PCT/US2015/062208); Ownership interest less than 5%: Gritstone Bio, Synthekine. RJS—Consulting fees: Asana Biosciences, AstraZeneca, Bristol Myers Squibb, Eisai, Iovance, Merck, Novartis, OncoSec, Pfizer, Replimune; Contracted research: Merck, Amgen. ES—Nothing to disclose. SITC Staff: PJI, CM—Nothing to disclose.

References

    1. Dobosz P, Dzieciątkowski T. The intriguing history of cancer Immunotherapy. Front Immunol 2019;10:2965. 10.3389/fimmu.2019.02965 - DOI - PMC - PubMed
    1. Kluger HM, Tawbi HA, Ascierto ML, et al. . Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy resistance Taskforce. J Immunother Cancer 2020;8:e000398. 10.1136/jitc-2019-000398 - DOI - PMC - PubMed
    1. Rizvi N, Ademuyiwa FO, Cao ZA, et al. . Society for Immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune Checkpoint inhibitors with chemotherapy. J Immunother Cancer 2023;11:e005920. 10.1136/jitc-2022-005920 - DOI - PMC - PubMed
    1. Atkins MB, Ascierto PA, Feltquate D, et al. . Society for Immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune Checkpoint inhibitors with targeted therapies. J Immunother Cancer 2023;11:e005923. 10.1136/jitc-2022-005923 - DOI - PMC - PubMed
    1. Kluger H, Barrett JC, Gainor JF, et al. . Society for Immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune Checkpoint inhibitors. J Immunother Cancer 2023;11:e005921. 10.1136/jitc-2022-005921 - DOI - PMC - PubMed